BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS).

• Tác giả: Naoya Akazawa, Toshiyuki Arai, Atsuki Arimoto, Hideto Fujita, Tohru Funakoshi, Hiroko Hasegawa, Takeshi Ishikawa, Toshiaki Ishikawa, Masato Kataoka, Yosuke Kito, Chihiro Kondoh, Hidekazu Kuramochi, Akitaka Makiyama, Dai Manaka, Toshiki Masuishi, Toshihiko Matsumoto, Hiroshi Matsuoka, Ayako Mishima, Toshikazu Moriwaki, Michitaka Nagase, Masato Nakamura, Masayoshi Nakanishi, Goro Nakayama, Yuji Negoro, Tomohiro Nishina, Hisatsugu Ohori, Osamu Okochi, Hiroyuki Okuda, Yasuhiro Sakamoto, Hironaga Satake, Takaya Shimura, Katsunori Shinozaki, Shinichiro Shinzaki, Manabu Shiozawa, Takeshi Suto, Nao Takano, Naoki Takegawa, Kunio Takuma, Hiroya Taniguchi, Yasushi Tsuji, Kay Uehara, Setsuo Utsunomiya, Takanori Watanabe, Toshifumi Yamaguchi
• Ngôn ngữ: eng
• Thông tin xuất bản: Switzerland : Cancers , 2025
• Bộ sưu tập: NCBI
• ID: 75778

Tóm tắt

BACKGROUND/OBJECTIVES: BRAF mutations occur in 5-10% of metastatic colorectal cancer (mCRC) cases, but their implications for prognosis and optimal treatment remain unclear. METHODS: This multicenter, prospective observational study analyzed 377 RAS wild-type cases from 511 patients across 32 centers, using PCR-based methods. RESULTS: BRAF mutations were identified in 21% (79/377) of cases, predominantly V600E (89.9%) with a minority of non-V600E (10.1%). Microsatellite instability (MSI) testing revealed MSI-high in 11.3%, exclusively among V600E cases. V600E mutations were linked to right-sided tumors, poor differentiation, and elevated CA19-9 levels. Median survival was significantly lower in V600E cases compared to BRAF wild-type (12.4 vs. 37.5 months, HR 3.25, CONCLUSIONS: These findings highlight distinct clinical and prognostic profiles for BRAF V600E and non-V600E mutations, while treatment choice appears to have limited impact on survival in these subgroups or RAS/BRAF wild-type cases.